Shuttle Pharmaceuticals Files S-1 for Highly Dilutive $3.5M Offering Amid Going Concern Warning
SHPH is trading near its 52-week low of $1.26 (10% above the low).
Summary
Shuttle Pharmaceuticals is seeking to raise up to $3.5 million in a highly dilutive public offering of common stock and pre-funded warrants, a crucial step for its survival given a 'going concern' warning and recent strategic shift to AI drug discovery.
Key Events · Financing and Capital Events · SHPH
-
Proposed Public Offering
The company plans to raise up to $3.5 million through a 'best efforts' public offering of common stock and pre-funded warrants, with an assumed offering price of $1.57 per share.
-
Extreme Dilution
The potential gross proceeds of $3.5 million represent approximately 88% of the company's current market capitalization, indicating substantial dilution for existing shareholders.
-
Critical Capital Infusion
This financing is essential for the company's continued operations, especially given its disclosed 'going concern' warning and a reported working capital deficit of $0.7M-$0.8M for the year ended December 31, 2025.
-
Strategic Pivot Funding
Proceeds will be used for marketing expenses ($1.5M) and general corporate purposes, supporting the company's recent acquisition of Molecule.ai and the discontinuance of its clinical trials.
Analysis · SHPH · Life Sciences
Shuttle Pharmaceuticals Holdings, Inc. has filed an S-1 registration statement for a proposed public offering to raise up to $3.5 million through the sale of common stock and pre-funded warrants. This offering is critical for the company's continued operations, as highlighted by its disclosed 'going concern' warning and preliminary unaudited financial results for 2025 showing a significant net loss and working capital deficit. The offering, which is a 'best efforts' arrangement with no minimum, is highly dilutive, representing approximately 88% of the company's current market capitalization. While the offering price of $1.57 per share was at market on February 5, 2026, it is above the current stock price of $1.39, indicating a potential premium for new capital. The proceeds are earmarked for marketing expenses and general corporate purposes, supporting the company's recent strategic pivot into AI-driven drug discovery following the acquisition of Molecule.ai and the discontinuance of its clinical trials.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.8% of the 571 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SHPH was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $1.26 to $19.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.